Cargando…
Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation
Immunotherapy is less effective in non-small cell lung cancer (NSCLC) with driver mutations in epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) and some may extrapolate this trend to other driver mutations. Up to 4% of NSCLC cases contain a BRAF mutation. Most BRAF mutatio...
Autores principales: | Rittberg, Rebekah, Banerji, Shantanu, Green, Susan, Qing, Gefei, Dawe, David E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704186/ https://www.ncbi.nlm.nih.gov/pubmed/33269152 http://dx.doi.org/10.7759/cureus.11224 |
Ejemplares similares
-
Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors
por: Rossi, Sabrina, et al.
Publicado: (2016) -
Response to Immunotherapy in Adenocarcinoma Lung With Gastric Metastasis: A Rare Case Report and Review of Literature
por: Das Majumdar, Saroj Kumar, et al.
Publicado: (2021) -
Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study
por: Dawe, David E., et al.
Publicado: (2023) -
Pulmonary Large Cell Neuroendocrine Carcinoma: A Rare Type of Non-Small Cell Lung Cancer
por: Ng, Thomas G, et al.
Publicado: (2021) -
Small Bowel Perforation Due to Rare Metastasis From Stage IV Lung Adenocarcinoma
por: Sautto, Francesco, et al.
Publicado: (2022)